Cerebral microbleeds and the risk of intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: systematic review and meta-analysis. by Charidimou, A et al.
SHORT REPORT
Cerebral microbleeds and the risk of intracerebral
haemorrhage after thrombolysis for acute ischaemic
stroke: systematic review and meta-analysis
Andreas Charidimou,1 Puneet Kakar,2 Zoe Fox,3,4 David J Werring1
▸ An additional supplementary
ﬁgure and supplementary
tables 1 to 3 are published
online only. To view these ﬁles
please visit the journal online
(http://dx.doi.org/10.1136/jnnp-
2012-303379).
1Stroke Research Group,
Department of Brain Repair and
Rehabilitation, UCL Institute of
Neurology and The National
Hospital for Neurology and
Neurosurgery, Queen Square,
London WC1N 3BG, UK
2Department of Stroke
Medicine, Imperial College
Healthcare, NHS Trust,
London, UK
3Biomedical Research Centre,
UCL, London, UK
4Education Unit, UCL Institute
of Neurology, London, UK
Correspondence to
Dr David J Werring,
Stroke Research Group,
Department of Brain Repair and
Rehabilitation, UCL Institute of
Neurology and National Hospital
for Neurology and Neurosurgery,
Box 6, Queen Square, London
WC1N 3BG, UK;
d.werring@ucl.ac.uk
Received 3 June 2012
Revised 13 August 2012
Accepted 28 August 2012
Published Online First
28 September 2012
ABSTRACT
Background Intracerebral haemorrhage (ICH) remains
the most devastating yet unpredictable complication of
intravenous thrombolysis for acute ischaemic stroke. We
performed a systematic review and meta-analysis, to
assess whether the presence of cerebral microbleeds
(CMBs) on prethrombolysis MRI scans is associated with
an increased risk of ICH.
Methods We searched PubMed for studies assessing
ICH risk in patients with acute ischaemic stroke treated
with thrombolysis, in relation to the presence of pre-
treatment CMBs.
Results We identiﬁed ﬁve studies including 790 patients
and pooled data in a meta-analysis. The CMB (+) versus
CMB (−) groups were not signiﬁcantly different in age,
gender or stroke severity. The overall prevalence of CMBs
was 135/790 (17.1%). Amongst patients with CMBs,
10/135 (7.4%) experienced a symptomatic ICH after
thrombolysis, compared to 29/655 (4.4%) patients
without CMBs. The pooled relative risk of ICH was 1.90
(95% CI 0.92 to 3.93; p=0.082).
Conclusions The available evidence does not
demonstrate a statistically signiﬁcant increased risk of
symptomatic ICH after thrombolysis for ischaemic stroke in
patients with CMBs. However, in view of the
methodological limitations of the studies included, the
clinical relevance of any potential hazard associated with
CMBs remains uncertain. Further studies are warranted to
evaluate whether the risk of ICH might outweigh the beneﬁt
of thrombolysis, especially in patients with multiple lobar
CMBs suggestive of cerebral amyloid angiopathy.
INTRODUCTION
Intravenous thrombolysis is the only effective
licensed treatment for acute ischaemic stroke.
However, the improved outcomes overall come at
the cost of a small increase in risk of intracerebral
haemorrhage (ICH), the most devastating yet
unpredictable complication.1 Symptomatic ICH
occurs in about 2.4–10% of cases within 24–36 h
of thrombolysis (depending on the deﬁnition
used), and may be disabling.1 2 Identifying patients
at higher risk for ICH following thrombolysis is
thus an urgent clinical priority: a reliable and safe
way to do this could increase the overall safety
proﬁle of this widely used treatment. Markers of
increased risk include increasing age, early ischae-
mic CT changes, high blood pressure, hypergly-
caemia, clinical stroke severity as assessed by the
National Institute of Health Stroke Scale score on
admission, large baseline diffusion lesion volume
and cerebral white matter changes (leukoaraiosis),
but there is currently no reliable way to predict
severe ICH.1 Cerebral microbleeds (CMBs)—small
perivascular haemorrhages seen as well-
demarcated, hypointense, rounded lesions on MRI
sequences sensitive to magnetic susceptibility—are
a marker of haemorrhage-prone microangiopathies
(mainly hypertensive arteriopathy or cerebral
amyloid angiopathy (CAA)). Because CMBs are a
rather speciﬁc marker for previous bleeding from
pathologically fragile cerebral small vessels,3 they
might help to identify a subpopulation of patients
at high risk of clinically signiﬁcant ICH.4 Previous
studies have given conﬂicting results regarding the
possible risk of ICH after thrombolysis in indivi-
duals with CMBs.5 6 We therefore performed a sys-
tematic review and meta-analysis to assess the
evidence whether the presence of CMBs on pre-
thrombolysis MRI scans is associated with an
increased risk of ICH.
METHODS
Search strategy and selection criteria
We searched PubMed between 1 January 1995 and
1 February 2012 using the following search terms:
‘microbleed(s)’, or ‘micro(-)h(a)emorrhage(s)’, or
‘gradient-echo’ in association with ‘thromboly*’ or
‘tPA’, or ‘tissue plasminogen activator ’. Reference
lists from all included articles and the authors’
own ﬁles were also searched for relevant publica-
tions. Papers not published in English and case
reports were excluded. Two authors (AC and PK)
identiﬁed potentially relevant studies, resolving
any uncertainties with a third author (DJW).
Eligibility criteria
Studies were eligible for inclusion if they had
assessed ICH risk in patients with acute ischaemic
stroke treated with thrombolysis, and quantiﬁed
this risk in relation to the presence of CMBs on
pretreatment MRI scans.
Data extraction
Two authors (AC and PK) went through all articles
selected as potentially relevant and extracted data
independently. We extracted information on type of
study, number and nature of participants (including
mean age and sex), MRI parameters, duration of
follow-up, number of participants with at least one
CMB and number of participants with the outcome
event (symptomatic ICH deﬁned according to stand-
ard criteria). Consensus was reached by discussion.
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Studies were critically appraised against a checklist of key quality
indicators with reference to the STROBE (STrengthening the
Reporting of OBservational studies in Epidemiology) statement
and the ideal characteristics for a study of CMBs7 (see online sup-
plementary table S1) (Clearly deﬁned CMB criteria, clear deﬁn-
ition of the study population, standardised MRI parameters,
clearly deﬁned ICH criteria, awareness of >2 CMB mimics, stan-
dardised rating scale or trained observer with reported inter-rater/
intra-rater agreement, data on CMB distribution and adjustment
for other ICH risk factors).
Meta-analysis
We used a ﬁxed effects model to calculate the pooled relative
risk (RR) of symptomatic ICH in patients with versus without
CMBs, where weights were calculated using the inverse vari-
ance method. We assessed heterogeneity using I-squared and
x-squared statistics and through visual inspection of the forest
plot. We explored publication bias with the funnel plot.
Meta-analyses were performed using Stata 11.2 (StataCorp LP,
Texas, USA). We prepared this report with reference to MOOSE
(meta-analyses of observational studies) guidelines.8
RESULTS
We identiﬁed 62 articles in our initial search of PubMed; ﬁve
studies including a total of 790 patients (135 with CMBs) met
our inclusion criteria, and were pooled in a meta-analysis.5 6 9–11
One study was excluded12 because of overlap with a previously
published cohort.6 A summary of the characteristics of included
studies is provided in table 1 and online supplementary tables S2
and S3. There was no evidence of publication bias in the funnel
plot (see online supplementary ﬁgure S1). The CMB (+) versus
CMB (−) groups were not signiﬁcantly different in age, gender
or stroke severity, except that in one study higher age was
associated with CMBs.6 The overall prevalence of CMBs on pre-
treatment MRI scans was 17.1%. Amongst patients with CMBs,
10/135 (7.4%) experienced a symptomatic ICH after thromboly-
sis, compared to 29/655 (4.4%) patients without CMBs; the
pooled RR of ICH was 1.90 (95% CI 0.92 to 3.93; p=0.082)
(ﬁgure 1). The results were consistent from study to study
(p=0.800).
DISCUSSION
Our systematic review and meta-analysis in nearly 800 patients
with acute ischaemic stroke shows that the presence of CMBs
on a pretreatment MRI scan is not associated with a statistic-
ally signiﬁcant increased risk of symptomatic ICH following
thrombolysis. However, there was a trend for a higher ICH risk
in those patients with CMBs (pooled RR 1.90; 95% CI 0.92 to
3.93; p=0.082).
With the introduction of T2*-weighted gradient-recalled
echo (T2*-GRE) and susceptibility-weighted imaging, CMBs
are increasingly detected in patients with acute ischaemic
stroke.4 Evidence suggests that CMBs are a prognostic marker
for future ICH risk after stroke.13 14 However, only ﬁve studies
have reported on the risk of ICH following thrombolysis for
acute ischaemic stroke in patients screened for CMBs.5 6 9–11
Recent studies indicate that the rate of symptomatic
thrombolysis-related ICH is increased in the presence of
moderate-to-severe leukoaraiosis, implying that cerebral small
vessel is a risk factor for ICH.15 16 However, leukoaraiosis lacks
pathological speciﬁcity, by contrast with CMBs, which appear
to speciﬁcally reﬂect small areas of haemorrhage from vessels
affected by bleeding-prone arteriopathies (mainly hypertensive
arteriopathy or CAA).3
Several methodological aspects of the included studies
deserve consideration. Importantly, most had a small sample
size; only the multicentre BRASIL (bleeding risk analysis in
stroke imaging before thromboLysis) study (n=570) had more
than 100 patients, and hence dominated our meta-analysis.6
Furthermore, all studies are subject to selection bias since not
all acute stroke patients undergo T2*-GRE, and such patients
were excluded.
Imaging parameters varied between studies, which could
affect the prevalence of CMBs.4 17 In some centres in the
BRASIL study6 a small proportion of stroke patients had
CMBs, and only six patients had ﬁve or more CMBs, suggest-
ing that some MRI protocols were not optimal to detect
CMBs, which are typically found in about 20–30% of ischae-
mic stroke patients;7 Moreover, the studies did not use standar-
dised rating scales for CMBs, and did not report on ICH risk in
relation to CMB number and anatomical location.
Although the outcome deﬁnitions for ICH were not standar-
dised among the studies included, all included ICH associated
with clinical deterioration and thus likely to be clinically relevant.
A range of different thrombolysis protocols were used (table 1
and online supplementary table S3): for example Kim et al9
included both intravenous and intra-arterial thrombolysis, but
found no statistically signiﬁcant difference between the groups
in haemorrhagic complications.9 The study by Derex et al11
included two drug doses but found no signiﬁcant inﬂuence of
dose on the risk of ICH.
Some studies did not provide full details of some baseline
characteristics likely to be important for thrombolysis-related
ICH, for example, hyperglycaemia, hypertension, prior use of
antiplatelet and anticoagulant medications or recurrent stroke.
CMBs might increase the risk of thrombolysis-related ICH
either as the direct source of the ICH, or as a general marker of
small vessel fragility. About 20% of patients with acute ischae-
mic stroke develop new CMBs in the ﬁrst few days,18 suggest-
ing an active, diffuse microangiopathy, which with the
administration of thrombolysis could cause symptomatic ICH.
Since most new CMBs in this study18 developed in patients
with baseline CMBs, prethrombolysis CMBs may be a marker
for patients at most risk of symptomatic ICH. However, the
free circulating plasma half-life of alteplase is very short
(between 4–6 min), and that the exact mechanisms of ICH
post-thrombolysis remain uncertain.
Deep CMBs in the basal ganglia and brainstem are most
likely related to hypertensive arteriopathy, while multiple
strictly lobar CMBs are likely to reﬂect CAA.4 CAA may be a
particular risk factor for post-thrombolysis ICHs, which are
often lobar, multiple and occur remote from the infarct in
around 20% of patients.19 Pathological studies also support a
role of pre-existing CAA: one study reported that 70% of
patients with thrombolysis-related ICH had autopsy-proven
CAA compared to 22% of unselected ICH patients of similar
age.20 Finally, an increased risk of ICH was associated with
intravenous thrombolysis in CAA transgenic mice.21 Strictly
lobar CMBs form an important part of recent diagnostic cri-
teria for CAA,22 so may be of particular prognostic value for
ICH, but this has not been addressed by previous studies.
CONCLUSIONS
Our analysis suggests a trend of increased risk of symptomatic
ICH after thrombolysis for ischaemic stroke if CMBs are present
on pretreatment MRI. Although the risk was not statistically
signiﬁcant at the 0.05 level, the data do not rule out a possible
clinically important increased hazard for thrombolysis in
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Table 1 Characteristics of included studies
Study Study design
Patient
number
(% men)
Mean age
(years)
Initial stroke
severity
(NIHSS)
T2*-GRE MRI parameters
CMBs
prevalence
(95% CI)
Differences
CMBs(+) versus
CMBs (−) groups
Thrombolysis
(see online
supplementary
table S3)
FU
time
(days)
Symptomatic
ICH definition
Other risk factors for
thrombolysis-related
ICH accounted for
Field
strength
(Tesla)
Echo time
(ms)
Section
thickness
(mm)
Fiehler
2007
Prospective,
multicentre (13)
570 (–) 69 (59–77)* 13 (IQR:8–17) – 14–49 5–7 15.1% (9.1
to 19.7%)
No differences in: sex
and NIHSS score.
Median age (IQR): 72
(65–79) versus 69 (58–
77); (p=0.001)
IV tPA within 6 h 10 ICH with
worsening of ≥4
points on NIHSS
–
Kim
2006
Retrospective,
single centre
65 (57) 67 – – 30 5 15.7% (8.1
to 26.4%)
Hypertension and age
associated with CMBs
(p<0.05)
IV tPA within 3 h
(n=12); IA UK
within 6 h
(n=53)
1–3 Symptomatic
haemorrhage:
any neurological
deterioration
within the first
48 h that could
be attributed to
the presence
haemorrhage on
follow-up MRI
Age, hypertension,
diabetes, atrial
fibrillation, stroke
history, smocking,
NIHSS score
Kakuda
2005
Prospective,
multicentre (3)
70
(44.3)
70.5 11±9.2/13±9.8
CMB (+)/(−)
(mean/SD)
1.5 14–47 5 38.5% (26.7
to 51.4%)
No differences in age,
time to treatment, blood
pressure, NIHSS,
hypertension. Diabetes,
dyslipidaemia, smoking
IV tPA within 6 h 30 ICH with
worsening of ≥2
points on NIHSS
–
Derex
2004
Retrospective,
single centre
44 (–) 63.2+/−14.1 14±5.8 (mean/
SD)
1.5 26 5 18.2% (8.2
to 32.7%)
– IV tPA at two
different doses
within 7 h
7 ICH with
worsening of ≥4
points on NIHSS
or ≥1 point on
NIHSS
consciousness
level
Delay to treatment;
tPA dose
Kidwell
2002
Retrospective,
single centre
41 (–) – – 1.5 15 7 12.2% (4.1
to 26.2%)
No differences in age,
hypertension, diabetes,
hypercholesterolaemia,
smoking, and severity of
pretreatment
neurological deficit.
IV/IA tPA within
3 h; IA UK or
tPA mechanical
clot disruption
during IA
thrombolysis
7 ICH with
worsening of ≥4
points on NIHSS
or ≥1 point on
NIHSS
consciousness
level
Thrombolysis regimen
CMB, cerebral microbleeds; FU, follow-up; GRE, gradient-recalled echo; IA: intra-arterial; ICH, intracerebral haemorrhage; IQR, interquartile range; IV, intravenous; NIHSS, National Institute of Health Stroke Scale; SD, standard deviation; tPA, tissue
plasminogen activator.
*Median age (interquartile range)
J
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individuals with CMBs, particularly in view of the signiﬁcant
methodological limitations of included reports. Our data thus
reinforce the need for further large multicentre studies (for sug-
gested ideal study characteristics see online supplementary
table S1) to evaluate whether the risk of ICH outweighs the
beneﬁt of thrombolysis in patients with CMBs, particularly
those with multiple lobar CMBs suggestive of CAA.23
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Figure 1 Meta-analysis of the association between intracerebral haemorrhage (ICH) risk in patients with acute ischaemic stroke treated with
thrombolysis, in relation to the presence of cerebral microbleeds (CMBs) on pretreatment MRI scans. This ﬁgure is only reproduced in colour in the
online version.
280 J Neurol Neurosurg Psychiatry 2013;84:277–280. doi:10.1136/jnnp-2012-303379
Cerebrovascular disease
